Cargando…

Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India

Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global health problem, India being the second most affected country. The kinetics of antibody response to SARS-CoV-2 in Indian population is not studied yet. To understand serological resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chidananda, Mohana Kumari, Zohmangaihi, Deepy, Ram, Sant, Soni, Shiv Lal, Suri, Vikas, Malhotra, Pankaj, Jassal, Ravjit Singh, Kaur, Jyotdeep, Verma, Indu, Sharma, Sadhna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212795/
https://www.ncbi.nlm.nih.gov/pubmed/34177138
http://dx.doi.org/10.1007/s12291-021-00986-x
_version_ 1783709707882463232
author Chidananda, Mohana Kumari
Zohmangaihi, Deepy
Ram, Sant
Soni, Shiv Lal
Suri, Vikas
Malhotra, Pankaj
Jassal, Ravjit Singh
Kaur, Jyotdeep
Verma, Indu
Sharma, Sadhna
author_facet Chidananda, Mohana Kumari
Zohmangaihi, Deepy
Ram, Sant
Soni, Shiv Lal
Suri, Vikas
Malhotra, Pankaj
Jassal, Ravjit Singh
Kaur, Jyotdeep
Verma, Indu
Sharma, Sadhna
author_sort Chidananda, Mohana Kumari
collection PubMed
description Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global health problem, India being the second most affected country. The kinetics of antibody response to SARS-CoV-2 in Indian population is not studied yet. To understand serological response in relation to age, gender, time period and severity of disease, Roche Elecsys anti-SARS-CoV-2 test was used which analysed both IgM and IgG. One hundred and three COVID-19 patients were enrolled. Seropositivity was seen in 64% of patients, with 33% at ≤ 7 days, 62% between 8 and 15 days and 81% at ≥ 16 days from the time of admission. Men (65%) showed higher antibody response than women (59%), whereas no difference was observed in seropositivity with respect to age of the patients. Dynamics of antibody responses revealed individual variations. Patients in ICU had higher antibody reactivity with 67% positivity as compared to 60% positivity in non-ICU patients. Kinetics of antibody response during COVID-19 disease varied in relation to gender, age, time period and severity and these factors might play an important role in treatment and control of COVID-19.
format Online
Article
Text
id pubmed-8212795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-82127952021-06-21 Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India Chidananda, Mohana Kumari Zohmangaihi, Deepy Ram, Sant Soni, Shiv Lal Suri, Vikas Malhotra, Pankaj Jassal, Ravjit Singh Kaur, Jyotdeep Verma, Indu Sharma, Sadhna Indian J Clin Biochem Original Research Article Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a global health problem, India being the second most affected country. The kinetics of antibody response to SARS-CoV-2 in Indian population is not studied yet. To understand serological response in relation to age, gender, time period and severity of disease, Roche Elecsys anti-SARS-CoV-2 test was used which analysed both IgM and IgG. One hundred and three COVID-19 patients were enrolled. Seropositivity was seen in 64% of patients, with 33% at ≤ 7 days, 62% between 8 and 15 days and 81% at ≥ 16 days from the time of admission. Men (65%) showed higher antibody response than women (59%), whereas no difference was observed in seropositivity with respect to age of the patients. Dynamics of antibody responses revealed individual variations. Patients in ICU had higher antibody reactivity with 67% positivity as compared to 60% positivity in non-ICU patients. Kinetics of antibody response during COVID-19 disease varied in relation to gender, age, time period and severity and these factors might play an important role in treatment and control of COVID-19. Springer India 2021-06-18 2021-10 /pmc/articles/PMC8212795/ /pubmed/34177138 http://dx.doi.org/10.1007/s12291-021-00986-x Text en © Association of Clinical Biochemists of India 2021, corrected publication 2021
spellingShingle Original Research Article
Chidananda, Mohana Kumari
Zohmangaihi, Deepy
Ram, Sant
Soni, Shiv Lal
Suri, Vikas
Malhotra, Pankaj
Jassal, Ravjit Singh
Kaur, Jyotdeep
Verma, Indu
Sharma, Sadhna
Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
title Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
title_full Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
title_fullStr Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
title_full_unstemmed Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
title_short Combined Analysis of Anti SARS-CoV-2 IgG and IgM Responses in COVID19 Patients in India
title_sort combined analysis of anti sars-cov-2 igg and igm responses in covid19 patients in india
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212795/
https://www.ncbi.nlm.nih.gov/pubmed/34177138
http://dx.doi.org/10.1007/s12291-021-00986-x
work_keys_str_mv AT chidanandamohanakumari combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT zohmangaihideepy combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT ramsant combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT sonishivlal combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT surivikas combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT malhotrapankaj combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT jassalravjitsingh combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT kaurjyotdeep combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT vermaindu combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia
AT sharmasadhna combinedanalysisofantisarscov2iggandigmresponsesincovid19patientsinindia